Table 1 Baseline characteristics of women and men*
| Â | Women n = 508 | Men n = 41 |
|---|---|---|
Age-years (SD) | 61.5 (11.3) | 57.8 (12.4) |
Height-cm (SD) | 160.8 (9.6) | 174.8 (18.3) |
Weight-kg (SD) | 67.8 (14.4) | 86.2 (22.0) |
Iliocostal distance-cm (SD) | 4.2 (1.6) | 4.6 (1.5) |
Menopausal status-#post/#pre | 424/78 | NA |
Age at menopause-years (SD) | 47.3 (6.8) | NA |
Lumbar spine BMD-g/cm2 (SD) | 0.867 (0.165) | 0.918 (0.165) |
Femoral neck BMD-g/cm2 (SD) | 0.664 (0.112) | 0.713 (0.124) |
Trochanter BMD-g/cm2 (SD) | 0.608 (0.107) | 0.676 (0.123) |
Ward's triangle BMD-g/cm2 (SD) | 0.483 (0.133) | 0.471 (0.155) |
Currently smoking-# | 64 | 6 |
Family history of fracture-# | 122 | 12 |
Alcohol-beverages/week (SD) | 1.4 (3.0) | 5.5 (8.7) |
Number of falls – min to max | 0–12 | 0–4 |
Calcium intake-mg/d (SD) | 539.0 (435.9) | 553.5 (375.4) |
Exercise-minutes/week (SD) | 166.7 (165.9) | 187.9 (293.0) |
Etidronate use-# (%) | 50 (9.8) | 3 (7.3) |
Alendronate use-# (%) | 41 (8.1) | 7 (17.1) |
Fluoride use-# (%) | 2 (0.4) | 0 (0.0) |
Raloxifene use-# (%) | 9 (1.8) | 0 (0.0) |
Hormone replacement use-# (%) | 146 (28.7) | 0 (0.0) |
Corticosteroids use-# (%) | 77 (15.2) | 8 (19.5) |
Calcium supplement use-# (%) | 366 (72.0) | 16 (39.0) |
Vitamin D supplement use-# (%) | 173 (34.1) | 10 (24.4) |
Lung diseasea-# (%) | 59 (11.6) | 3 (7.3) |
Liver diseaseb-# (%) | 13 (2.6) | 2 (4.9) |
Thyroid diseasec-# (%) | 69 (13.6) | 0 (0.0) |
Cancerd-# (%) | 14 (2.8) | 0 (0.0) |
Visual impairment-# (%) | 51 (10.0) | 2 (4.9) |
Osteoporosis-# (%) | 187 (36.8) | 13 (31.7) |
Inflammatory bowel disease-# (%) | 15 (3.0) | 5 (12.2) |
Epilepsy-# (%) | 7 (1.4) | 2 (4.9) |
Coronary disease-# (%) | 12 (2.4) | 1 (2.4) |
Cerebrovascular disease-# (%) | 19 (3.7) | 1 (2.4) |
Rheumatoid arthritis-# (%) | 5 (1.0) | 0 (0.0) |
Diabetes-# (%) | 18 (3.5) | 0 (0.0) |
Kidney failure-# (%) | 24 (4.7) | 0 (0.0) |